Compare AU

Compare PAVE vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X Us Infrastructure Development ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are PAVE and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

PAVE

CURE

Popularity

Low

Low

Pearlers invested

6

80

Median incremental investment

$1,493.50

$620.00

Median investment frequency

Fortnightly

Monthly

Median total investment

$2,569.44

$1,290.82

Average age group

> 35

> 35


Key Summary

PAVE

CURE

Strategy

PAVE.AX was created on 2024-06-03 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Indxx U.S. Infrastructure Development Index.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Global X Us Infrastructure Development ETF (100 %)

Neurocrine Biosciences Inc (2.71 %)

Alnylam Pharmaceuticals Inc (2.47 %)

Biomarin Pharmaceutical Inc (2.47 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.47 %

0.45 %


Key Summary

PAVE

CURE

Issuer

Global X

Global X

Tracking index

Indxx U.S. Infrastructure Development Index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.47 %

0.45 %

Price

$12.12

$48.71

Size

$11.352 million

$36.961 million

10Y return

N/A

N/A

Annual dividend/ distribution yield (5Y)

- %

4.24 %

Market

ASX

ASX

First listed date

04/06/2024

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

PAVE

CURE

Popularity

Low

Low

Pearlers invested

6

80

Median incremental investment

$1,493.50

$620.00

Median investment frequency

Fortnightly

Monthly

Median total investment

$2,569.44

$1,290.82

Average age group

> 35

> 35


Pros and Cons

PAVE

CURE

Pros

  • Higher price growth

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

  • Lower price growth

PAVE

CURE

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home